AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36803273 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (physiological saline (1 ml))
Number of subjects: 117
Study 36803273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 117
Study 36803273 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 117
Study 36803315 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with integrated, immersive, multimodal, therapeutic VR for 12 weeks
Number of subjects: 120
Study 36803315 — intervention group
Group type: COMPARATOR
Intervention: Usual primary physiotherapy care for 12 weeks
Number of subjects: 120
Study 36803406 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual supervised tooth brushing program
Number of subjects: 1192
Study 36803406 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1192
Study 36803412 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold spinal cord stimulation (paresthesia-free SCS)
Number of subjects: 114
Study 36803412 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 114
Study 36803444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower standardized involuntary care ratios
Number of subjects: 0
Study 36803444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized involuntary care ratios in 2014-2017
Number of subjects: 0
Study 36803444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized involuntary care ratios in 2015
Number of subjects: 0
Study 36803465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salovum (egg yolk powder enriched for antisecretory factor) during concomitant radiochemotherapy
Number of subjects: 8
Study 36803508 — intervention group
Group type: COMPARATOR
Intervention: Prebiotic formula (fructo- and galactooligosaccharides)
Number of subjects: 0
Study 36803508 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formula (prebiotic formula with Lactobacillus paracasei ssp. paracasei F19)
Number of subjects: 0
Study 36803632 — intervention group
Group type: EXPERIMENTAL
Intervention: ZF2001 (25 μg, three doses, intramuscularly, 30 days apart)
Number of subjects: 475
Study 36803632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 36803632 — intervention group
Group type: EXPERIMENTAL
Intervention: ZF2001
Number of subjects: 475
Study 36803640 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation whole genome sequencing on the Illumina platform
Number of subjects: 537
Study 36803645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib monotherapy
Number of subjects: 66
Study 36803645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 66
Study 36803645 — intervention group
Group type: COMPARATOR
Intervention: Concomitant mutations from multiple pathways in HER2-related signaling network
Number of subjects: 66
Study 36803647 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-based two-drug therapy
Number of subjects: 228
Study 36803647 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-based three-drug therapy
Number of subjects: 228
Study 36803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome composition at baseline
Number of subjects: 111
Study 36803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal samples and extensive host metadata
Number of subjects: 111
Study 36803654 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY individuals
Number of subjects: 64
Study 36803654 — intervention group
Group type: COMPARATOR
Intervention: XY controls
Number of subjects: 64
Study 36803673 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutionary Systems Therapy for Schizotypy (experimental treatment)
Number of subjects: 24
Study 36803673 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy and psychopharmacological treatment (control)
Number of subjects: 24
Study 36803737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution (OCS) administered before surgery
Number of subjects: 50
Study 36803737 — intervention group
Group type: COMPARATOR
Intervention: Fasting from midnight till surgery (Control)
Number of subjects: 50
Study 36803737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution (OCS)
Number of subjects: 50
Study 36803773 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 0
Study 36803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (M-Body), eight weekly, 90-min group sessions
Number of subjects: 274
Study 36803835 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 274
Study 36803837 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Number of subjects: 280
Study 36803837 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Number of subjects: 280
Study 36803837 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Number of subjects: 280
Study 36803837 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Number of subjects: 280
Study 36803837 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgical systemic antibiotic therapy
Number of subjects: 280
Study 36803840 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks
Number of subjects: 24
Study 36803840 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks + BCG (50 mg) induction and maintenance
Number of subjects: 24
Study 36803840 — intervention group
Group type: COMPARATOR
Intervention: BCG (50 mg) induction and maintenance
Number of subjects: 24
Study 36803840 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 24
Study 36803873 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS-3 group (pre-admission GOS score of 3)
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Age above 59 years
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Preexisting ultimately fatal comorbidity
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Refractory CSE
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Cerebral insult as the cause of CSE
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Logistic Organ Dysfunction score ≥ 3 at ICU admission
Number of subjects: 499
Study 36803873 — intervention group
Group type: COMPARATOR
Intervention: Preadmission GOS score of 3
Number of subjects: 499
Study 36803892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid injection
Number of subjects: 78
Study 36803992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral ivermectin (600 µg/kg daily for 7 days)
Number of subjects: 205
Study 36803992 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies casirivimab and imdevimab (600 mg/600 mg)
Number of subjects: 205
Study 36803992 — intervention group
Group type: COMPARATOR
Intervention: No study drug
Number of subjects: 205
Study 36804035 — intervention group
Group type: EXPERIMENTAL
Intervention: Obex®
Number of subjects: 160
Study 36804035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 36804035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 36804046 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanQuit alone
Number of subjects: 444
Study 36804046 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanQuit+Motiv8 combined
Number of subjects: 444
Study 36804046 — intervention group
Group type: COMPARATOR
Intervention: Florida Quitline
Number of subjects: 444
Study 36804053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4) added to atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF)
Number of subjects: 0
Study 36804053 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF)
Number of subjects: 0
Study 36804053 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 36804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 1405
Study 36804093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1405
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen 100 mg
Number of subjects: 49
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen 200 mg
Number of subjects: 49
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen 300 mg
Number of subjects: 49
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen 400 mg
Number of subjects: 49
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen 600 mg
Number of subjects: 49
Study 36804094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 36804094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baliforsen
Number of subjects: 49
Study 36804149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild local hyperthermia
Number of subjects: 0
Study 36804149 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 0
Study 36804173 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn photoplethysmography (PPG) sensor for heart rate (HR) and respiratory rate (RR) measurements
Number of subjects: 62
Study 36804286 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT-A 500U
Number of subjects: 186
Study 36804286 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT-A 300U
Number of subjects: 186
Study 36804286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 36804322 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose group (4 mg total carotenoids/d, 177 mL orange-carrot juice/d)
Number of subjects: 162
Study 36804322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (8 mg total carotenoids/d, 355 mL orange-carrot juice/d)
Number of subjects: 162
Study 36804322 — intervention group
Group type: COMPARATOR
Intervention: Control group (negligible carotenoids, 177 mL apple juice/d)
Number of subjects: 162
Study 36804420 — intervention group
Group type: EXPERIMENTAL
Intervention: FMNCP intervention (16 coupon sheets valued at $21 per sheet over 10-15 wk)
Number of subjects: 285
Study 36804420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 285
Study 36804420 — intervention group
Group type: EXPERIMENTAL
Intervention: FMNCP intervention
Number of subjects: 285
Study 36804420 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 36804450 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention including motivational interviewing and behavioral activation for 12 months
Number of subjects: 800
Study 36804450 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 36804834 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaL regimen (high-dose linezolid, bedaquiline, and pretomanid)
Number of subjects: 93
Study 36805024 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief four-module ICBT program (n = 22)
Number of subjects: 43
Study 36805024 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 43
Study 36805083 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with AAV8-LSPhGAA (1.6 × 10^13 vg/kg)
Number of subjects: 0
Study 36805083 — intervention group
Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study 36805095 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 107
Study 36805095 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calorie intake
Number of subjects: 107
Study 36805095 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 107
Study 36805095 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial protein (≥0.4 g/kg/d) or calorie (≥5 kcal/kg/d) gap between targeted or actual intake
Number of subjects: 107
Study 36805095 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus, male sex, higher BMI, in-hospital infections, necessity for invasive mechanical ventilation
Number of subjects: 107
Study 36805108 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (25% reduction in energy intake)
Number of subjects: 219
Study 36805108 — intervention group
Group type: COMPARATOR
Intervention: Control (ad libitum diet)
Number of subjects: 219
Study 36805169 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning approach using smartwatch data
Number of subjects: 22
Study 36805169 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model features
Number of subjects: 22
Study 36805181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DI)
Number of subjects: 40
Study 36805181 — intervention group
Group type: COMPARATOR
Intervention: Control (before DI)
Number of subjects: 40
Study 36805437 — intervention group
Group type: EXPERIMENTAL
Intervention: ag-hCG
Number of subjects: 64
Study 36805437 — intervention group
Group type: EXPERIMENTAL
Intervention: atg-hCG
Number of subjects: 64
Study 36805437 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist trigger
Number of subjects: 64
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than a college degree
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Female parent gender
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age in years
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater social support scores
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 300
Study 36805477 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social support
Number of subjects: 300
Study 36805499 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined tastes
Number of subjects: 0
Study 36805499 — intervention group
Group type: EXPERIMENTAL
Intervention: Food pictures dominant in specific taste qualities
Number of subjects: 0
Study 36805537 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length (TL)
Number of subjects: 137
Study 36805552 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 0
Study 36805552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Household conflicts (general, internal, and external)
Number of subjects: 1065
Study 36805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Household conflicts (without multimorbidity)
Number of subjects: 1065
Study 36805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Household conflicts (with multimorbidity and low SES)
Number of subjects: 1065
Study 36805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Household conflicts (without multimorbidity and high SES)
Number of subjects: 1065
Study 36805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent health complaints
Number of subjects: 1065
Study 36805638 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite coronary artery bypass grafting strategy (bridge)
Number of subjects: 208
Study 36805638 — intervention group
Group type: COMPARATOR
Intervention: Conventional grafting strategy
Number of subjects: 208
Study 36805638 — intervention group
Group type: COMPARATOR
Intervention: Composite coronary artery bypass grafting strategy (bridge) and Conventional grafting strategy
Number of subjects: 208
Study 36805672 — intervention group
Group type: EXPERIMENTAL
Intervention: Surf Therapy
Number of subjects: 96
Study 36805672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hike Therapy
Number of subjects: 96
Study 36805672 — intervention group
Group type: COMPARATOR
Intervention: Both Surf and Hike Therapies
Number of subjects: 96
Study 36805692 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Anywhere with Community Paramedics (CACP) program
Number of subjects: 0
Study 36805692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36805694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Number of subjects: 240
Study 36805694 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostrations (Tibetan Buddhist tradition)
Number of subjects: 240
Study 36805694 — intervention group
Group type: EXPERIMENTAL
Intervention: Koan Mu (Zen Buddhist tradition)
Number of subjects: 240
Study 36805694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror exercise (Toltec tradition)
Number of subjects: 240
Study 36805694 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness (control group)
Number of subjects: 240
Study 36805707 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin (3 times/day for 5 days)
Number of subjects: 150
Study 36805707 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (Placebo)
Number of subjects: 150
Study 36805707 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin
Number of subjects: 150
Study 36805758 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week virtual peer support programme
Number of subjects: 160
Study 36805758 — intervention group
Group type: COMPARATOR
Intervention: Usual care (provision of online information resources via MND Association website)
Number of subjects: 160
Study 36805772 — intervention group
Group type: EXPERIMENTAL
Intervention: sLRP1 levels
Number of subjects: 64
Study 36805772 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sLRP1 levels
Number of subjects: 64
Study 36805796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental well-being intervention (six face-to-face visits by psychiatric nurses after a 3-day training course)
Number of subjects: 87
Study 36805796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental well-being intervention
Number of subjects: 87
Study 36805833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ato-Dro 80-5 mg
Number of subjects: 15
Study 36805833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ato-Dro 80-10 mg
Number of subjects: 15
Study 36805833 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine alone
Number of subjects: 15
Study 36806067 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the pectoral fascia (PF)
Number of subjects: 21
Study 36806067 — intervention group
Group type: COMPARATOR
Intervention: Removal of the pectoral fascia (PF)
Number of subjects: 21
Study 36806068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (TCS) during an AD flare
Number of subjects: 81
Study 36806068 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic dicloxacillin/placebo and TCS during an AD flare
Number of subjects: 81
Study 36806068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous exposure to autologous material
Number of subjects: 81
Study 36806068 — intervention group
Group type: COMPARATOR
Intervention: Untreated AD flare
Number of subjects: 81
Study 36806073 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (Airmid) with monthly questionnaires for 90 days
Number of subjects: 0
Study 36806136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined asynchronous telemonitoring and patient-initiated follow-up
Number of subjects: 200
Study 36806136 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 36806283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 2
Study 36806283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 36806898 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (DT)
Number of subjects: 160
Study 36806898 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 160
Study 36807080 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 234
Study 36807080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 234
Study 36807215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the first and second molars for 10 seconds per point at 16 different points.
Number of subjects: 20
Study 36807215 — intervention group
Group type: COMPARATOR
Intervention: Contralateral side of the intervention group (no laser treatment).
Number of subjects: 20
Study 36807215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment).
Number of subjects: 20
Study 36807273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-long 48 mm drug-eluting stent (DES)
Number of subjects: 649
Study 36807273 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug-eluting stent (DES)
Number of subjects: 649
Study 36807378 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless VVI
Number of subjects: 6219
Study 36807456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 1707
Study 36807456 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 1707
Study 36807465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (600 μg/kg daily for 6 days)
Number of subjects: 1206
Study 36807465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1206
Study 36807465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 1206
Study 36807505 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted arm (risk-guided model)
Number of subjects: 4447
Study 36807505 — intervention group
Group type: COMPARATOR
Intervention: Universal arm (universal offering of PrEP)
Number of subjects: 4447
Study 36807512 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Balloon (PB)
Number of subjects: 402